Sun Pharmaceutical Industries Ltd

Sun Pharma.Inds. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharmaceutical Industries Ltd

₹ 1,708 0.48%
14 May - close price
sunpharma.com BSE: 524715 NSE: SUNPHARMA
About

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

Key Points

Product Offerings
The company produces a range of generic and specialty medications for chronic and acute conditions. Its product portfolio includes generics, branded generics, specialty pharmaceuticals, advanced technology-based products, antiretrovirals, active pharmaceutical ingredients (APIs), and intermediates. It offers medications in multiple dosage forms, such as injectables, sprays, ointments, creams, liquids, tablets, and capsules. [1] [2]The company offers 26+ products in the global specialty market, with a strategic focus on dermatology, ophthalmology, and onco-dermatology segments. [3]

Website BSE NSE
  • Market Cap ₹ 4,09,854 Cr.
  • Current Price ₹ 1,708
  • High / Low ₹ 1,960 / 1,377
  • Stock P/E 34.8
  • Book Value ₹ 288
  • Dividend Yield 0.79 %
  • ROCE 17.3 %
  • ROE 16.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 23.4% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 46.6%

Cons

  • The company has delivered a poor sales growth of 10.8% over past five years.
  • Tax rate seems low

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Sensex Nifty 50 BSE 500 BSE Healthcare BSE 100

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
9,863 9,447 10,762 10,952 11,241 10,931 11,941 12,192 12,381 11,983 12,653 13,291 13,675
7,257 7,106 7,877 7,996 8,237 8,129 8,609 9,013 8,904 8,948 9,045 9,352 9,666
Operating Profit 2,606 2,340 2,884 2,957 3,004 2,802 3,332 3,179 3,477 3,035 3,608 3,939 4,009
OPM % 26% 25% 27% 27% 27% 26% 28% 26% 28% 25% 29% 30% 29%
433 -3,822 2 85 174 202 -118 294 180 504 533 354 149
Interest 19 37 14 19 46 93 81 49 35 74 62 69 52
Depreciation 554 556 588 610 660 672 651 633 622 650 655 626 631
Profit before tax 2,466 -2,076 2,285 2,412 2,471 2,240 2,481 2,791 3,000 2,816 3,424 3,598 3,476
Tax % 14% 7% 8% 6% 11% 10% 19% 14% 14% 5% 16% 16% 16%
2,126 -2,227 2,093 2,256 2,181 1,983 2,006 2,385 2,561 2,659 2,861 3,037 2,913
EPS in Rs 8.58 -9.49 8.59 9.43 9.03 8.27 8.43 9.90 10.52 11.06 11.82 12.67 12.10
Raw PDF
Upcoming result date: 22 May 2025

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
11,131 16,080 27,392 28,487 31,578 26,489 29,066 32,838 33,498 38,654 43,886 48,497 51,602
6,346 9,078 19,498 20,313 21,476 20,858 22,689 25,855 25,028 28,397 32,235 35,479 37,012
Operating Profit 4,784 7,003 7,894 8,174 10,102 5,631 6,377 6,983 8,470 10,258 11,650 13,018 14,591
OPM % 43% 44% 29% 29% 32% 21% 22% 21% 25% 27% 27% 27% 28%
-90 -1,968 283 -42 610 -135 -258 382 -3,449 -3,505 459 865 1,540
Interest 43 44 579 523 400 518 555 303 141 127 172 238 256
Depreciation 336 409 1,195 1,038 1,265 1,500 1,753 2,053 2,080 2,144 2,529 2,557 2,562
Profit before tax 4,315 4,581 6,403 6,571 9,048 3,479 3,810 5,010 2,799 4,481 9,408 11,088 13,313
Tax % 20% 15% 14% 14% 13% 26% 16% 16% 18% 24% 9% 13%
3,469 3,879 5,476 5,658 7,846 2,542 3,208 4,172 2,272 3,389 8,513 9,610 11,470
EPS in Rs 14.40 15.17 21.92 18.89 29.03 8.73 11.11 15.69 12.10 13.64 35.32 39.91 47.65
Dividend Payout % 9% 10% 14% 5% 12% 23% 25% 25% 62% 73% 33% 34%
Compounded Sales Growth
10 Years: 12%
5 Years: 11%
3 Years: 13%
TTM: 9%
Compounded Profit Growth
10 Years: 8%
5 Years: 23%
3 Years: 25%
TTM: 26%
Stock Price CAGR
10 Years: 6%
5 Years: 31%
3 Years: 24%
1 Year: 12%
Return on Equity
10 Years: 14%
5 Years: 14%
3 Years: 16%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 104 207 207 241 240 240 240 240 240 240 240 240 240
Reserves 14,886 18,318 25,431 32,742 36,400 38,074 41,169 45,025 46,223 47,771 55,755 63,427 68,875
260 2,561 8,996 8,497 9,832 10,385 10,514 8,315 3,869 1,290 6,886 3,274 2,572
5,128 8,009 14,089 13,948 14,624 15,598 12,666 14,615 17,291 20,474 17,831 18,367 16,429
Total Liabilities 20,377 29,095 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,308 88,116
5,647 6,817 12,682 15,872 17,675 18,853 21,837 22,847 21,553 22,665 24,065 23,211 28,318
CWIP 563 842 2,039 2,175 2,801 2,465 1,411 1,220 1,567 1,287 4,973 5,354 1,150
Investments 2,412 2,786 2,716 1,830 1,192 7,143 7,903 10,143 9,612 12,849 14,824 15,026 17,744
11,756 18,650 31,286 35,550 39,427 35,837 33,439 33,984 34,890 32,975 36,849 41,717 40,904
Total Assets 20,377 29,095 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,308 88,116

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
3,357 3,959 5,616 6,686 7,082 3,907 2,196 6,555 6,170 8,985 4,959 12,135
-2,375 -2,176 -1,502 -3,949 -4,186 -3,104 -310 -2,225 407 -5,556 -7,220 -763
-665 507 -1,187 -1,889 -2,285 -1,539 -2,731 -5,715 -5,980 -5,193 2,376 -6,710
Net Cash Flow 316 2,290 2,927 848 611 -736 -844 -1,386 596 -1,765 115 4,662

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 79 50 68 87 83 108 112 105 99 99 95 85
Inventory Days 454 410 307 370 307 338 366 311 378 315 360 338
Days Payable 186 174 178 207 197 234 192 142 167 158 194 194
Cash Conversion Cycle 347 286 197 251 193 212 285 274 310 255 261 229
Working Capital Days 111 126 76 104 73 79 137 112 84 55 93 78
ROCE % 32% 34% 23% 18% 20% 10% 10% 10% 13% 17% 16% 17%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48%
14.95% 16.00% 16.87% 16.88% 16.48% 16.78% 17.08% 17.72% 17.23% 18.01% 18.04% 17.96%
19.66% 19.64% 19.08% 19.18% 19.65% 19.56% 19.42% 18.71% 19.17% 18.48% 18.43% 18.58%
0.00% 0.06% 0.06% 0.06% 0.09% 0.10% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
10.91% 9.80% 9.52% 9.38% 9.28% 9.05% 8.92% 8.97% 9.00% 8.89% 8.92% 8.86%
No. of Shareholders 6,47,1676,43,5126,32,3376,25,2526,24,5616,16,5886,12,6266,31,3926,73,2176,57,3176,89,6237,04,983

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls